| Literature DB >> 25170330 |
Ali Eatemadi1, Hadis Daraee1, Hamzeh Karimkhanloo1, Mohammad Kouhi2, Nosratollah Zarghami1, Abolfazl Akbarzadeh3, Mozhgan Abasi1, Younes Hanifehpour4, Sang Woo Joo4.
Abstract
Current discoveries of different forms of carbon nanostructures have motivated research on their applications in various fields. They hold promise for applications in medicine, gene, and drug delivery areas. Many different production methods for carbon nanotubes (CNTs) have been introduced; functionalization, filling, doping, and chemical modification have been achieved, and characterization, separation, and manipulation of individual CNTs are now possible. Parameters such as structure, surface area, surface charge, size distribution, surface chemistry, and agglomeration state as well as purity of the samples have considerable impact on the reactivity of carbon nanotubes. Otherwise, the strength and flexibility of carbon nanotubes make them of potential use in controlling other nanoscale structures, which suggests they will have a significant role in nanotechnology engineering.Entities:
Keywords: Carbon nanostructures; Drug delivery; Flexibility; Nanotubes; Toxicity
Year: 2014 PMID: 25170330 PMCID: PMC4141964 DOI: 10.1186/1556-276X-9-393
Source DB: PubMed Journal: Nanoscale Res Lett ISSN: 1556-276X Impact factor: 4.703
Figure 1Schematic structure and TEM images of SWCNT and MWCNT. (A) Schematic structure of SWCNT and (B) MWCNT. The transmission electron microscope (TEM) images of a (C) SWCNT and (D) MWCNT [6-8].
Figure 2Different forms of SWNTs. (A) The chiral vector C also determines the tube diameter. (B) Models of three atomically perfect SWCNT structures [10].
Comparison between SWNT and MWNT[4]
| Single layer of graphene | Multiple layers of graphene |
| Catalyst is required for synthesis | Can be produced without catalyst |
| Bulk synthesis is difficult as it requires proper control over growth and atmospheric condition | Bulk synthesis is easy |
| Purity is poor | Purity is high |
| A chance of defect is more during functionalization | A chance of defect is less but once occurred it is difficult to improve |
| Less accumulation in the body | More accumulation in the body |
| Characterization and evaluation is easy | It has very complex structure |
| It can be easily twisted and is more pliable | It cannot be easily twisted |
The physical properties of carbon nanotubes
| Equilibrium structure | Average diameter of SWNTs | 1.2 to 1.4 nm |
| | Distance from opposite carbon atoms (line 1) | 2.83 Å |
| | Analogous carbon atom separation (line 2) | 2.456 Å |
| | Parallel carbon bond separation (line 3) | 2.45 Å |
| | Carbon bond length (line 4) | 1.42 Å |
| | C-C tight bonding overlap energy | Approximately 2.5 eV |
| | Group symmetry (10, 10) | C5V |
| | Lattice: bundles of ropes of nanotubes | Triangular lattice (2D) |
| Lattice constant | | 17 Å |
| Lattice parameter | (10, 10) Armchair | 16.78 Å |
| | (17, 0) Zigzag | 16.52 Å |
| | (12, 6) Chiral | 16.52 Å |
| Density | (10, 10) Armchair | 1.33 g/cm3 |
| | (17, 0) Zigzag | 1.34 g/cm3 |
| | (12, 6) Chiral | 1.40 g/cm3 |
| Interlayer spacing: | ( | 3.38 Å |
| | ( | 3.41 Å |
| | (2 | 3.39 Å |
| Optical properties | | |
| Fundamental gap | For ( | 0 eV |
| | For ( | Approximately 0.5 eV |
| Electrical transport | | |
| | Conductance quantization | (12.9 k O )-1 |
| | Resistivity | 10-4 O -cm |
| | Maximum current density | 1,013 A/m2 |
| Thermal transport | | |
| | Thermal conductivity | Approximately 2,000 W/m/K |
| | Phonon mean free path | Approximately 100 nm |
| | Relaxation time | Approximately 10 to 11 s |
| Elastic behavior | | |
| | Young's modulus (SWNT) | Approximately 1 TPa |
| | Young's modulus (MWNT) | 1.28 TPa |
| Maximum tensile strength | Approximately 100 GPa | |
Summary and comparison of three most common CNT synthesis methods
| Yield rate | >75% | >75% | >75% |
| SWNT or MWNT | Both | Both | Both |
| Advantage | Simple, inexpensive, high-quality nanotubes | Relatively high purity, room-temperature synthesis | Simple, low temperature, high purity, large-scale production, aligned growth possible |
| Disadvantage | High temperature, purification required, tangled nanotubes | Method limited to the labscale, crude product purification required | Synthesized CNTs are usually MWNTs, defects |
Application of nanotube as artificial implants
| Porous SWCNT | Polycarbonate membrane | Osteoblast-like cells | Increase lamellipodia (cytoskeletal) extensions, and lamellipodia extensions | [ |
| SWCNT-incorporated | Chitosan scaffolds | C2Cl2 cells /C2 myogenic cell line | Cell growth improvement | [ |
| MWCNT | Collagen sponge honeycomb scaffold | MC3T3-E1 cells, a mouse osteoblast-like cell line | Increase cellular adhesion and proliferation | [ |
| MWCNT | Polyurethane | Fibroblast cells | Enhance interactions between the cells and the polyurethane surface | [ |
| SWCNT | Alginate | Rat heart endothelial cell | Enhance cellular adhesion and proliferation | [ |
| MWCNT | Poly(acrylic acid) | Human embryonic stem cells | Increase cellular differentiation toward neurons | [ |
| SWCNT | Propylene fumarate | Rabbit tibia | Support cell attachment and proliferation | [ |
Example of detection of cancer biomarker by carbon nanotubes
| P-type carbon nanotubes | Prostate-specific antigen (PSA) | Prostate cancer | [ |
| Multilabel secondary antibody-nanotube bioconjugates | Prostate-specific antigen (PSA) | Prostate cancer | [ |
| Microelectrode arrays modified with single-walled carbon nanotubes (SWNTs) | Total prostate-specific antigen (T-PSA) | Prostate cancer | [ |
| Multiwalled carbon nanotubes-thionine-chitosan (MWCNTs-THI-CHIT) nanocomposite film | Chlorpyrifos residues | Many forms | [ |
| Carbon nanomaterial | Carcinoma antigen-125 (CA125) | Carcinoma | [ |
| MWCNT-platinum nanoparticle-doped chitosan (CHIT) | AFP | Many forms | [ |
| Poly- | Carbohydrate antigen 19–9 (CA19-9) | Many forms | [ |
| MWCN-polysulfone (PSf) polymer | Human chorionic gonadotropin (hCG) | Many forms | [ |
| Multiwalled carbon nanotube-chitosan matrix | Human chorionic gonadotropin (hCG) | Many forms | [ |
| MWCNT-glassy carbon electrode (GCE) | Prostate-specific antigen (PSA) | Prostate cancer | [ |
| Nanoparticle (NP) label/immunochromatographic electrochemical biosensor | Prostate-specific antigen (PSA) | Prostate cancer | [ |
| SWNT-horseradish peroxidase (HRP) | Prostate-specific antigen (PSA) | Prostate cancer | [ |
| Carbon nanotube field effect transistor (CNT-FET) | Prostate-specific antigen (PSA) | Prostate cancer | [ |
| Carbon nanoparticle (CNP)/poly(ethylene imine) (PEI)-modified screen-printed graphite electrode (CNP-PEI/SPGE) | Carcinoembryonic antigen (CEA), | Urothelial carcinoma | [ |
| Tris(2,2′-bipyridyl)cobalt(III) (Co(bpy)33+)- MWNTs-Nafion composite film | Carcinoma antigen-125 (CA125) | Carcinoma | [ |
| Gold nanoparticles and carbon nanotubes doped chitosan (GNP/CNT/Ch) film | Alpha-fetoprotein (AFP) | Many forms | [ |
| Multiple enzyme layers assembled multiwall carbon nanotubes (MWCNTs) | Alpha-fetoprotein (AFP) | Many forms | [ |
Example of drugs and nucleic acids which were delivered by carbon nanotubes
| Taxoid | SWNTs | Leukemia | High potency toward specific cancer cell lines | [ |
| Doxorubicin | SWNTs | Colon cancer | Efficiently taken up by cancer cells, then translocates to the nucleus while the nanotubes remain in the cytoplasm | [ |
| Cisplatin | SWNTs | Squamous carcinoma | Rapid regression of tumor growth | [ |
| Cisplatin | SWNTs | Nasopharyngeal epidermoid carcinoma, etc. | High and specific binding to the folate receptor (FR) for the SWNT-1 conjugate | [ |
| Doxorubicin | SWNTs | Breast cancer Glioblastoma | Show that large surface areas on single-walled carbon nanotubes (SWNTs) | [ |
| Doxorubicin | SWNTs | Cervical carcinoma | Increase nuclear DNA damage and inhibit the cell proliferation | [ |
| Radionuclide | SWNTs | Burkitt lymphoma | The selective targeting of tumor in vitro and in vivo | [ |
| Paclitaxel | SWNTs | Breast cancer | High treatment efficacy, minimum side effects | [ |
| siRNA | SWNTs | Tumor cells both in vitro and in vivo mouse models | Increase suppression of tumor growth | [ |
| Toxic siRNA sequence (siTOX) | Functionalized MWNTs | Human lung xenograft model | Significant tumor growth inhibition | [ |
| siRNA | SWNT | Human neuroblastoma | Enhance the efficiency of siRNA-mediated gastrin-releasing peptide receptor (GRP-R) gene silencing | [ |
| sWNT | Dendritic cells (DCs) | Reduced | [ |